Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2022 | Unmet needs in multiple sclerosis

Jeffrey Cohen • 24 Feb 2022
ACTRIMS 2022
Multiple Sclerosis and Related Disorders

Jeffrey A. Cohen, MD, Cleveland Clinic, Cleveland, OH, talks on major research priorities, both preclinical and clinical, in the multiple sclerosis (MS) space. Dr Cohen emphasizes the development of reparative agents and treatments for progressive disease as areas of particular need. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.

More from Jeffrey Cohen

1:09
Ozanimod: long-term safety and efficacy in relapsing MS
Jeffrey Cohen • 24 Feb 2022
1:35
ACTRIMS research priorities
Jeffrey Cohen • 24 Feb 2022
1:13
How to approach MS treatment sequencing in a crowded therapeutic market
Jeffrey Cohen • 24 Feb 2022
1:15
Developing novel biomarkers in MS: diagnostic, predictive, & prognostic
Jeffrey Cohen • 24 Feb 2022

Related Videos

1:59
Exciting remyelination research in MS: cell therapy and neuromodulation
Giancarlo Comi • 23 Mar 2024
2:30
The potential of wearables for continuous activity monitoring in MS
Giancarlo Comi • 23 Mar 2024
3:19
Is MS progressive from onset? Challenging the classical understanding of progression
Giancarlo Comi • 23 Mar 2024
1:50
BTK inhibitors for MS treatment: what do the recent trial readouts mean for the field?
Giancarlo Comi • 23 Mar 2024
The content of VJNeurology is intended for healthcare professionals